Trial Profile
A Phase 2a Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole IR, Given With Ondansetron in Patients With Major Depressive Disorder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary) ; Pramipexole (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Chase Pharmaceuticals
- 05 Oct 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2024.
- 05 Oct 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2024.
- 22 Apr 2022 Planned End Date changed from 30 May 2021 to 30 Dec 2022.